P-tau217 is a form of phosphorylated tau that can be measured in the blood. It is considered an important biomarker of the biological changes associated with Alzheimer’s disease.
Levels of p-tau217 can rise during the early stages of Alzheimer’s-related pathology, potentially before noticeable symptoms develop. However, individuals with a similar p-tau217 biomarker level may experience different clinical trajectories.
The apolipoprotein E (APOE) gene is involved in lipid transport and brain health, and the APOE-ε4 variant is an established genetic risk factor for Alzheimer’s disease compared with people who do not carry it.
Now, new research suggests that while higher levels of p-tau217 may signal a greater risk of cognitive impairment, a person’s genetic background could help determine how quickly that impairment develops.
The findings, published in The Lancet Neurology, suggest that APOE-ε4 status may provide information about the timing of cognitive decline.
The results suggest that combining p-tau217 measurements with APOE genotype could eventually help researchers better identify people at higher risk of cognitive decline and determine who may benefit from closer monitoring.
Researchers pooled participant-level data from prospective cohort studies involving older adults from diverse racial and ethnic backgrounds, involving participants recruited through community settings and academic research centers in the United States, Canada, and the Dominican Republic. These included:
The pooled analysis included 8,582 people, with a mean age of 70 years. About 66% of participants were female, and 34% were male. Approximately 47% of participants were non-Hispanic White, 16% were Black, and 37% were Hispanic or belonged to other ethnic groups.
The study included people who were cognitively healthy but considered at increased risk of dementia, as well as participants with mild cognitive impairment or dementia. Rather than estimating when symptoms might develop based on a predicted age of onset, the researchers used observed clinical follow-up data to investigate both the risk and timing of cognitive impairment.
Higher baseline p-tau217 concentrations were associated with greater odds of having cognitive impairment at the time of assessment. The relationship was particularly strong among people who carry the APOE-ε4 allele.
“The most important takeaway is that plasma p-tau217 appears to provide information not only about the presence of Alzheimer’s disease-related pathology, but also about the risk and timing of future cognitive impairment, and that this prognostic meaning differs by APOE genotype,” Dung Trinh, MD, internist, of MemorialCare Medical Group and Chief Medical Officer of Healthy Brain Clinic in Irvine, CA, who was not involved in the study, told Medical News Today.
“In the pooled analysis, higher p-tau217 was associated with greater odds of cognitive impairment and with earlier incident cognitive impairment, with consistently stronger associations among APOE-ε4 carriers. This suggests that p-tau217 may be most informative when interpreted in the context of an individual’s genetic background rather than as a stand-alone biomarker.”
— Dung Trinh, MD
A similar pattern emerged when researchers looked at the participants over time. Higher baseline p-tau217 was associated with an increased likelihood of developing cognitive impairment during follow-up, with the association again being stronger among APOE-ε4 carriers.
Additionally, the researchers found that APOE-ε4 status was also relevant for how quickly cognitive impairment emerged.
For APOE-ε4 carriers, every 1-standard-deviation increase in p-tau217 was associated with a 24% shorter period before cognitive impairment. For non-carriers, the corresponding reduction was 13%.
Among people with comparable p-tau217 concentrations, those carrying APOE-ε4 appeared more likely to progress to cognitive impairment and to do so sooner.
“The most plausible interpretation is that APOE-ε4 carriers may move more quickly from underlying Alzheimer’s disease pathology to clinically detectable impairment,” Trinh explained to MNT. “One possible explanation is that APOE-ε4 may accelerate or amplify the downstream effects of Alzheimer’s disease pathology.”
“In the analyses, each 1-SD increase in p-tau217 was associated with a 24% shorter time to cognitive impairment in APOE-ε4 carriers, compared with 13% in non-carriers, and the survival curves began to diverge more clearly after several years of follow-up. That pattern is consistent with the idea that APOE-ε4 may affect not just whether pathology develops, but the pace at which pathology translates into symptoms.”
— Dung Trinh, MD
The findings highlight an important challenge in using blood biomarkers to estimate future cognitive health.
While p-tau217 levels may indicate the presence or likelihood of Alzheimer’s-related pathology, the same biomarker concentration may not carry exactly the same prognostic meaning for everyone.
In particular, the researchers found that the relationship between p-tau217 and cognitive impairment appeared stronger among non-Hispanic White participants than among other racial and ethnic groups.
However, the researchers did not find significant evidence that APOE-ε4 modified this relationship by race or ethnicity. This distinction is important because genetic and blood-based biomarkers are increasingly being studied as tools for identifying people at risk of Alzheimer’s disease.
Therefore, these findings support the idea that combining multiple sources of information, rather than relying on a single biomarker, could yield more individualized risk estimates.
Although encouraging, the findings should be interpreted in light of several limitations. Most cohorts provided only a single p-tau217 measurement, meaning the study could not fully assess how changes in biomarker levels over time relate to cognitive trajectories.
Differences in laboratory assays, clinical follow-up, and study designs may also have affected the results. Additionally, the outcome combined cognitive impairment of different types, rather than focusing exclusively on Alzheimer’s disease.
The researchers also noted limitations related to the categorization of racial and ethnic groups and incomplete information on kidney function, which may affect blood biomarker concentrations.
Importantly, the study shows an association between p-tau217, APOE-ε4, and cognitive impairment. However, it does not establish that either factor directly causes cognitive decline in an individual.
The findings suggest that the APOE genotype could add useful prognostic information to plasma p-tau217 measurements, particularly when estimating the risk and potential timing of cognitive impairment.
However, more research is necessary before such an approach can be used routinely to predict an individual’s future cognitive state. This will likely require studies involving broader populations worldwide, repeated measurements of p-tau217, and additional genetic information, such as polygenic risk scores.
“The findings suggest that cognitively unimpaired individuals with higher p-tau217, particularly APOE-ε4 carriers, may represent a group at greater near-term risk and therefore could be especially relevant for closer monitoring, prevention trials, or early-intervention studies,” Trinh concluded.
“However, the study does not establish a clinical treatment threshold or prove that earlier intervention based on this combination improves outcomes, so prospective validation and clinical trials are still needed before this approach is used routinely to guide treatment decisions.”
— Dung Trinh, MD
For now, the study adds to the growing evidence that Alzheimer’s risk is influenced by multiple factors and that the interpretation of a biomarker result may depend in part on the genetic background of the person being tested.
